Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025BiomedicinesOpen Access

Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRosemary T. SmithMDMary Kathryn DahlgrenKSKelly A. Sagar

Discussion

Loading...

Member takes

Overview

Open-label trial shows reductions in anxiety and improvements in quality of life for patients, suggesting potential benefits of hemp-derived CBD.

Key Points

  • Patients reported significant reductions in anxiety symptoms over time, indicating potential effectiveness of the treatment.
  • Clinical assessments showed concurrent improvements in mood, sleep, and quality of life domains alongside cognitive performance.
  • The open-label pilot clinical trial involved 12 patients, assessing the effects of CBD over six weeks with self-administered treatment.
  • Findings suggest promising efficacy and tolerability, calling for further rigorous studies to validate results in larger populations.

Cite This Study

Smith et al. (2025) studied this question.

synapsesocial.com/papers/68c2404eb210217d6479a062https://doi.org/10.3390/biomedicines13081874
View Full Paper
Ask AI
Bookmark
Share